Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBยทNASDAQ

$4.05

-3.3%
HealthcareMedical - Devices

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

At a Glance

Live Snapshot
Market Cap$523.03M
EPS-0.5200
P/E Ratio-7.79
Earnings Date08/05/2026
3Y-62.0%
5Y-131.0%
10Y-66.0%
3Y-118.0%
5Y-754.0%
10Y-1140.0%
3Y-344.0%
5Y-111.0%
10Y-14543.0%
CTKB

Cytek Biosciences, Inc. Cash Conversion Engine

CTKB ยท NASDAQ
Net Income-66.54M
Depreciation & Amortization11.97M
Stock-Based Compensation24.59M
Change in Working Capital-4.79M
Others-3.47M
Capital Expenditures-4.08M
Free Cash Flow-8.77M

Cash Flow Quality Analysis

FCF Conversion Rate

13.2%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

-87.2%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-140.1%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$4.79M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

Cytek Biosciences, Inc. Cash Flow Statement

CTKB โ€ข NASDAQ

Cytek Biosciences, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
OPERATING ACTIVITIES
-66.5M
-6M
-12.1M
2.5M
3M
19.4M
-16.8M
12M
10.5M
9.2M
5.7M
1.2M
603K
309K
33.6M
-2.9M
0.0
0.0
0.0
0.0
0.0
24.6M
26.8M
22M
16.6M
6.6M
611K
269K
-3.5M
-10.8M
-3.3M
3M
2.4M
2.1M
1.3M
(0.0)
(3.8M)
(5.3M)
(10.4M)
(2.9M)
(2.1M)
(144K)
-4.8M
7.7M
-10.5M
-39.9M
-8.6M
-7.5M
1.2M
-4.7M
25.4M
5.3M
-12.2M
4.6M
15.2M
-13.7M
INVESTING ACTIVITIES
-4.1M
-3.5M
-4.6M
-9.7M
-4.4M
-1.5M
-973K
(252K)
-471K
-45.1M
(0.0)
-16.6M
(0.0)
(0.0)
-278.2M
-274.1M
-175.9M
-46M
(0.0)
(0.0)
(0.0)
292.2M
195M
132M
0.0
0.0
0.0
0.0
-107K
84K
-179K
-120K
0.0
0.0
0.0
(10.1M)
-83M
-93.9M
-55.9M
-21M
-1.5M
-973K
FINANCING ACTIVITIES
-13.6M
-21.6M
-44.2M
0.0
215.7M
0.0
0.0
837K
3.6M
-565K
2.9M
-2.8M
2.8M
0.0
-15.1M
-21.6M
-44.2M
(0.0)
(0.0)
(0.0)
(0.0)
-669K
2.2M
2.9M
2.6M
642K
169K
93K
-13.4M
-15.8M
-41.8M
5.5M
213.6M
122.6M
93K
CASH FLOW SUMMARY
109K
4.5M
-1.4M
-2.5M
1.3M
-587K
-33K
-7.9M
-68.9M
-131.9M
-65.1M
198.5M
135.6M
-14.7M
98.7M
167.6M
299.5M
364.6M
166.1M
30.5M
45.2M
90.9M
98.7M
167.6M
299.5M
364.6M
166.1M
30.5M
-8.8M
21.9M
454K
-22.1M
266K
13.6M
-14.7M

SEC Filings

CTKB - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 02, 2026
May 27, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 28, 2026
June 10, 2026
2026
10-K

10-K 2025 FY

FY

February 26, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2026

N/A

January 13, 2026
January 12, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
8-K

8-K 2025

N/A

August 06, 2025
August 06, 2025
2025
Showing 1 to 10 of 70 filings